Bayer and Kimitec to launch new biological crop aids

Bayer and Spain-based biotechnology firm Kimitec have announced the development of two biological crop performance products—Ambition Complete Gen2 and Ambition Secure Gen2—currently undergoing regulatory review ahead of commercial release. The products are expected to join Bayer’s Crop Performance Enhancer portfolio as part of its strategy to expand offerings in regenerative agriculture.

The formulations were co-developed at Kimitec’s MAAVi Innovation Center, where researchers integrate microbiology, natural chemistry, artificial intelligence, and agronomic expertise to produce biologically driven solutions for the field. Ambition Complete Gen2 is a gel-based product designed to support nutrient uptake, plant stress tolerance, and metabolic efficiency. Ambition Secure Gen2 is aimed at improving calcium mobility and absorption in plants, a long-standing challenge in horticulture, with implications for fruit firmness and quality.

“This launch is not simply an enhancement of what already exists, but a true leap forward in how agricultural solutions are designed,” said Alejandro de las Casas, Kimitec’s agro-business director.

Ralf Glaubitz, head of Bayer’s CP Product Team for fungicides, biologics, and fruits and vegetables, said the partnership “sets a new standard for how to bring solutions to market fast, focused, and farmer-first.” He added that Bayer’s role in development and global distribution aims to integrate bio-based inputs more effectively into existing agricultural systems.

The collaboration underscores a broader shift in crop input strategies, as chemical majors respond to tightening regulations and rising demand for lower-residue alternatives. Biological products, often derived from natural sources, are increasingly seen as complementary tools within integrated farm management systems that also include crop protection chemicals, genetic technologies, and digital platforms.

If approved, both products are expected to reach commercial markets within the next one to two years, with initial focus likely on high-value specialty crops in Europe and other regions with established regulatory pathways for biologicals.